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Lydon Wainaina Nyambura  1, Alejandro Azorin Muñoz1, philipp le Coutre2 & peter Walden  1
Leukemia-associated antigens (LAAs) and HLA-I epitopes published previously have shown promise 
in inducing leukemia-specific T cell responses. However, the clinical responses are limited, and clinical 
effectiveness is yet to be achieved. Limitations, among others, being the LAAs themselves, the indirect 
approach to HLA-I epitope identification by reverse immunology, and the use of single or few LAAs and 
HLA-I epitopes, which limits the spectrum of inducible tumor-specific T cells. Use of a direct approach 
to identify naturally processed and presented HLA-I epitopes from LAAs, and higher numbers of 
antigens for T cell-mediated immunotherapy for leukemia may enhance clinical responses and broaden 
clinical effectiveness. In a prior study we used immunoaffinity purification of HLA-I peptide complexes 
from the differentiated myeloid tumor cell lines MUTZ3 and THP1 coupled to high-performance liquid 
chromatography tandem mass spectrometry (LC-MS/MS). From this we identified in the current study 
seven new HLA-I epitopes and the corresponding LAAs for myeloid leukemia. In comparison, the 
myeloid HLA-I epitopes reported here were generally stronger HLA-binders that induce stronger T cell 
responses than those previously published, and their source LAAs had higher immunogenicity, higher 
expression levels in myeloid tumors cells compared to normal hemopoietin and other major normal 
tissues, and more protein interaction partners, and they are targeted by CD8 T cells in CML patients. 
This study analyses and compares the LAAs and HLA-I epitopes based on various immunotherapeutic 
targets selection criteria, and highlights new targets for T cell-mediated immunotherapy for leukemia.
Cancer is the second leading cause of mortality worldwide and accounted for 8.8 million deaths in 20151 with 
a projection of 13 million deaths in 2030. Leukemia, a group of hematological malignancies that encompasses 
acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic 
lymphocytic leukemia (CLL) and other less common types, are among the 10 major cancers worldwide. They 
account for estimated 13.7 cases per 100,000 individuals per year and a five year survival rate of 61.4% (National 
Cancer Institute (NCI), Surveillance Epidemiology and End Results (SEER) 2008–2014; www.seer.cancer.gov).
Chemotherapy, radiotherapy, immunomodulatory drugs, proteasome inhibitors and hematopoietic stem cell 
transplantation (HSCT) have been used to treat hematological malignancies, though several of these are still 
incurable2,3. This is mostly due to the persistence of measurable minimal residual disease (MRD), which leads to 
high relapse rates4,5. So far, the only established immunotherapeutic approach is allogeneic stem cell transplanta-
tion, which has been shown to be essential in achieving long-term remissions6–9. However, it is associated with a 
high morbidity and mortality due to graft-versus-host activity of donor lymphocytes, and remains an option for 
only a fraction of patients10–12.
The alternative strategy to abolish MRD would be to use targeted T cell therapy, consisting of either adoptive 
transfer of T cells including use of chimeric antigen receptors (CARs) specific for leukemia-associated antigens 
(LAAs), or vaccination against LAAs13,14. Experimental leukemia immunotherapy using adoptive transfer of 
tumor antigen-specific T cells showed high efficiency but also severe toxicity in some patients due to previously 
unrecognized expression of target tumor antigen in vital organ15. On the other hand, a peptide based vaccine is an 
option and a number of T cell epitopes from LAAs have been identified based on gene expression profile analysis 
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coupled to reverse immunology of computer-based T cell epitope prediction algorithms. Selected peptides based 
on this approach from Wilm’s tumor 1 (WT1)7,14,16–22, receptor for hyaluronan-mediated motility (RHAMM)23,24, 
telomerase reverse transcriptase (TERT)25, proteinase-3 (PRNT 3)16 and survivin25 alone or in combination, have 
already been tested in clinical trials. They have shown promising results in terms of induction of specific T cell 
responses as well as clinical responses in some patients14,18,21,26–28. However, broad clinical effectiveness is yet to 
be achieved. The limitations, among others, may be the choice of target LAAs, the indirect epitope identification, 
which is mostly based on overexpressed genes in leukemia patients compared to healthy individuals coupled to 
reverse immunology, and use of single or limited number of LAAs and epitopes, thereby limiting the spectrum 
of inducible tumor-specific T cell responses. The peptide identification criterion disregards the fact that mRNA 
expression reflects a distorted picture of the situation on the cell surface as detectable for T cells, and T cell 
epitopes can still be identified despite the absence of detectable respective mRNA29. This highlights the need for 
re-examination of LAAs and identification of new targets for T cell-mediated immunotherapy for leukemia like 
AML and CML.
In a prior study30, we used a direct method of target identification: immunoaffinity purification of human 
leukocyte antigen I (HLA-I) peptide complexes from the antigen-presenting immature and mature dendritic cells, 
and macrophages derived from the myeloid cell lines MUTZ3 and THP1 coupled to liquid chromatographic tan-
dem mass spectrometry (LC-MS/MS). These cell lines were established originally from leukemia cells obtained 
from patients. In the current study we characterized HLA-I epitopes from potential LAAs (pLAAs), and com-
pared the peptides and their source proteins with published HLA-I epitopes from established LAAs (eLAAs) 
based on experimental and predicted HLA-I binding affinities, ability to stimulate T cells, overall immunogenic-
ity, gene expression profiles in leukemia and normal hematopoietic cells as well as major normal human tissues, 
and known protein interaction partners.
Results
Naturally presented HLA I epitopes from leukemia-associated antigens. In our previous HLA 
peptidome analysis of the myeloid tumor cell lines MUTZ3 DCs and THP1MФ by LC-MS/MS30 the cells were 
lysed, MHC class I molecules isolated by affinity chromatography, and peptides extracted from the MHC mole-
cules analyzed by LC-MS/MS. The sequences of a total of 975 HLA class I-bound peptides were identified from 
852 source proteins30. From this data, HLA I epitopes from pLAA P141-MBOA7, P130-LARP1, P378-TRRAP, 
P207-PININ, P308-ROS1, P114-PSME3, P57-UHRF1 and P326-URP2 were identified (Table 1). These antigens 
but not the epitopes had been described previously for other malignancies and hematological indications31–49. 
In our HLA peptidome analysis, we had not identified any HLA I-bound epitopes from the eLAAs Proteinase 3, 
WT1, PRAME, Survivin, RHAMM, hTERT and CML66 that had previously been identified by reverse immunol-
ogy of T cell epitope prediction algorithms (Table 2). To determine whether the lack of identification would be 
due to the lack of expression of the eLAAs in MUTZ3- and THP1- derived cells, RT-PCR was carried out using 
sequence-specific primers for the eLAA genes (Table 3). K562 and Molt4 cell lines were used as positive con-
trols for RHAMM and hTERT respectively, and β actin as control for the PCR reaction. As shown in (Fig. 1 and 
Supplementary Fig. 1A–F), Survivin was expressed in MUTZ3 iDCs, MUTZ3 mDCs and THP1MФ, Proteinase 
3 and CML66 in MUTZ3 mDC and THP1MФ, PRAME in MUTZ3 iDC and WT1 in THP1MФ. Expression of 
RHAMM and hTERT was not detected.
Peptide binding by HLA-I. Binding of HLA I-restricted eLAA epitopes previously identified from 
P300-PRAME, P540-hTERT, P165-RHAMM, P187-WT1 and P169-PRTN 3 by reverse immunology using T 
cell epitope prediction algorithms (Table 2), and of epitopes from P141-MBOA7, P130-LARP1, P378-TRRAP, 
P207-PININ, P308-ROS1, P114-PSME3, P57-UHRF1 and P326-URP2 identified by LC-MS/MS from the pep-
tidomes of the myeloid cell lines MUTZ3 and THP1 HLA-I (Table 1) was determined with a HLA-A*02:01 
positive TAP deficient T2 lymphoblastic cell line. The peptide binding evaluated by flow cytometry based on 
the mean fluorescence intensity (MFI) values from three independent experiments was in descending order 
Protein Peptide Sequence Peptide Source
Protein Role in Cancer
(Reference)
MBOA7 P141-MBOA7 GLLPDVPSL MUTZ3 iDC 31–33
LARP1 P130-LARP1 ALPPVLTTV MUTZ3 mDC 34,35
TRRAP P378-TRRAP TLADLVHHV MUTZ3 mDC 36–38
PININ P207-PININ RLLEQKVEL THP1MФ 39–41
ROS1 P308-ROS1 HLVDEAHCLRL THP1MФ 42–46
PSME3 P114-PSME3 QLVDIIEKV THP1MФ 47
URP2 P326-URP2 ALSNLEVKL THP1MФ 48,49
UHRF1 P57_UHRF1 TLFDYEVRL THP1MФ 71,72
Table 1. HLA-A*02:01 epitopes derived from leukemia-associated antigens (LAAs) from MUTZ3 DCs and 
THP1MФ HLA-I peptidomes (potential leukemia-associated antigens (pLAA))30. MBOA7, Lysophospholipid 
acetyltransferase 7; LARP1, La-related protein 1; TRRAP. transformation/transcription domain-associated 
protein; PININ, 140 kDa nuclear and cell adhesion-related phosphoprotein; ROS1, proto-oncogene tyrosine-
protein kinase ROS; PSME3, proteasome activator complex subunit 3; URP2, femitin family homolog 3; UHRF1, 
E3 ubiquitin-protein ligase UHRF.
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P187-WT1 (236.16 ± 46.68) > P169-PRTN 3 (181.31 ± 42.47) > P300-PRAME (172.84 ± 18.59) > P540-hTERT 
(171.74 ± 16.67) > P165-RHAMM (67.40 ± 11.90) and P141-MBOA7 (249.31 ± 21.31) > P57-UHRF1 
(215.82 ±  19.62) >  P326-URP2 (207.33 ±  17.49) >  P130-LARP1 (170.09 ±  57.83) >  P378-TRRAP 
(161.77 ± 33.39) > P207-PININ (126.49 ± 35.89) > P308-ROS1 (116.25 ± 25.63) > P114-PSME3 (108.71 ± 14.64) 
for eLAAs and pLAAs HLA-I peptides, respectively. The MFI for without peptide (negative control) and 
P564-HIVPol (positive control) was 39.82 ± 4.16 and 199.91 ± 18.89, respectively. Except for P165-RHAMM, for 
all tested peptides the MFI values were twofold and above that of negative control (Fig. 2A).
Using the position-based amino acid scores in the epitope prediction algorithm SYFPEITHI the pep-
tide ranking was P540-hTERT (30) > P169-PRTN 3, P165-RHAMM (28) > P300-PRAME (27) and 
P141-MBOA7 (32) > P130-LARP1 (30) > P378-TRRAP (29) > P207-PININ (28) > P326-URP2, P114-PSME3 
(27) > P57-UHRF1 (25) for eLAAs and pLAAs HLA-I peptides, respectively (Fig. 2B). The score for P308-ROS1 
was undetermined as no 11-mer prediction matrices for HLA-A*02:01 are defined with SYFPEITHI. The peptide 
binding affinities predicted by the ANN 4.0 algorithm in IEDB using a binding affinity threshold of IC50(500)nM 
was in the order P540-hTERT (0.14) > P187-WT1, P169-PRTN 3 (0.10) > P300-PRAME (0.09) > P165-RHAMM 
(0.01) for eLAAs HLA-I peptides and P378-TRRAP (0.25) > P57-UHRF1 > P141-MBOA7 (0.13) > P130-LARP1 
(0.06) > P114-PSME3 (0.04) > P207-PININ (0.03) > P308-ROS1, P326-URP2, P165-RHAMM (0.01) for pLAAs 
HLA-I peptides (Fig. 2C). The peptide binding affinities predicted by the NetMHCpan 4.0 in IEDB using the same 
binding affinity threshold was similar to that of ANN 4.0 for pLAAs HLA-I peptides with profound differences in 
eLAAs HLA-I peptides prediction output (Fig. 2C,D). Binding affinity prediction for the P564-HIVpol peptide 
LLFGXPVYV was not possible by ANN 4.0 and NetMHCpan 4.0 in IEDB due to the undefined amino acid at 
position 5. Correlation of the peptide ranking was low among the four methods when the peptides were ordered 
from highest to lowest affinity binder in the T2 HLA I stabilization assay, despite similarities in the prediction 
output for pLAAs HLA-I peptides by ANN 4.0 and NetMHCpan 4.0 in IEDB (Fig. 2E).
T cell responses to the established and peptidome epitopes. To determine specific CD8+ T cell 
responses to eLAAs (Table 2) and pLAAs HLA-I peptides (Table 1), PBMCs from 4 HLA-A*02:01 healthy donors 
and 8 HLA-A*02:01 CML patients in chronic stage were stimulated for 7 days with the individual peptides with 
IL-2 addition at day 1 and 3, and analyzed for epitope-specific T cells by INFγ ELISpot assays as detailed in 





hTERT P540-hTERT ILAKFLHWL 73,74
PRAME P300-PRAME ALYVDSLFFL 75–79
WT1 P187-WT1 SLGEQQYSV 80,81
RHAMM P165-RHAMM ILSLELMKL 23,24,78,82
PRTN 3 P169-PRTN 3 VLQELNVTV 14,26
Table 2. Clinically tested HLA-A*02:01 epitopes from established leukemia-associated antigens (eLAAs). 
hTERT, human telomerase reverse transcriptase; PRAME, melanoma antigen preferentially expressed in 
tumors; WT1, Wilm’s tumor protein; RHAMM, hyaluronan mediated motility receptor; PRTN3, Proteinase 3.








F: GCGGAGAACAAACTGAAC 333 65
363
R: AGAAGTCAGGGAAAAGGC 696 65
WT1
F: TAAAGGGAGTTGCTGCTG 307 65
380
R: GGTGTCTTTTGAGCTGGT 687 65
PRAME
F: TGAAAATGGTGCAGCTGG 679 65
154
R: CGGGGAAATGTAGGAAGA 833 65
Survivin
F: CCACCGCATCTCTACATT 47 65
129
R: GAAGAAACACTGGGCCAA 176 65
RHAMM
F: GCCTTAAGCAGTCTCTTG 808 65
381
R: CTTTCAGCTTGTTCCTCC 1189 65
hTERT
F: ATGAGTGTGTACGTCGTC 1644 65
270
R: CGTAGTCCATGTTCACAATC 1914 66
CML66
F: GTCAGTGCCACATTATGCTG 686 68
214
R: CCTCCTTAGTACTGTCTTC 900 65
ß-actin
F: AGGAGAAGCTGTGCTACGTC 722 59
454
R: CTCGTCATACTCCTGCTTGC 1176 58
Table 3. RT-PCR primer sequences.
4Scientific RepoRtS |         (2019) 9:14029  | https://doi.org/10.1038/s41598-019-50341-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
changes were seen in the frequencies in pre and post peptide-primed PBMCs (Supplementary Fig. 2). Based 
on Spots forming units (SFU) per 5 × 104 CD8+ T cells the T cell responses from the 4 healthy donors in the 
ELISpot assay was below 41 ± 23 for both eLAAs and pLAAs HLA-I peptides (Fig. 3). For the 8 CML patients 
the order was P187-WT1 (54 ± 93) > P540-hTERT (39 ± 62) > P165-RHAMM (33 ± 44) > P300-PRAME 
(32 ± 31) > P169-PRTN 3 (15 ± 18) and P326-URP2 (147 ± 318) > P141-MBOA7 (63 ± 144) > P378-TRRAP 
(55 ± 91) > P114-PSME3 (47 ± 59) > P308-LARP1 (47 ± 59) > P207-PININ (36 ± 36) > P57-UHRF1 
(30 ± 63), P130 > ROS1 (17 ± 32) for eLAAs and pLAAs HLA-I peptides, respectively (Fig. 3). P326-URP2 and 
P141-MBOA7 elicited the highest T cell responses and P169-PRTN 3 the lowest.
Immunogenicity of the LAAs. The immunogenicity of eLAAs and pLAAs was assessed by reverse immu-
nology epitope prediction applied for the most frequent HLA alleles HLA-A*01:01, HLA-A*02:01, HLA-A*11:01, 
HLA-A*24:02, HLA-C*04:01, HLA-C*06:02, HLA-C*07:01 and HLA-C*07:02 that together represent more than 
90% of the human population. NetMHCpan 4.0 in the IEDB was used with a binding affinity threshold of IC50 
(500 nM). The immunogenicity score is represented as 1/IC50(500 nM) and has a value of 0 to 1 for low to high 
immunogenicity. The immunogenicity of the LAAs varied depending the HLA allele (Fig. 4) and was generally 
highest for HLA-C*07:02 and lowest for HLA-A*02:01. The immunogenicity of both eLAAs and pLAAs for all 
the alleles was comparable, with median score of less than 0.4 for all LAAs.
LAA gene expression in myeloid leukemia vs normal hematopoietic, and major normal tissues. 
The gene expression profiles of the LAAs (eLAAs and pLAAs) in CML, AML and normal human hematopoietic 
cells were compared using the Bloodspot database50 as detailed in material and methods. Only WT1 and PRAME 
expression was significantly higher in AML compared to normal hematopoietic cells *P < 0.05, and PRAME in 
CML (Fig. 5). The expression of ROS1 was elevated but not significant. The expression of the other LAAs in CML 
and AML cells was similar to those of normal human hematopoietic cells. The expression of the LAAs in CML 
and AML cells varied and, in decreasing order as per medium log2 expression values, was for CML in the order 
PRTN3 (10) > RHAMM (6.5) > hTERT (6) > PRAME (4.5) > ROS1 (3.6) > WT1 3.5 and PININ (11.5) > LARP1 
Figure 1. Expression of established leukemia-associated antigens (eLAAs) in MUTZ3 DCs and THP1MФ. RT-
PCR showing expression of Proteinase 3, WT1, PRAME, Survivin, RHAMM, hTERT and CML66 in MUTZ3 
DCs and THP1MФ. β actin was used as a control for the PCR reactions, a positive control (cDNA from cells 
positive for the respective antigen), and negative control (PCR minus cDNA) were included. All positive 
bands were of the predicted amplicon size. Proteinase 3 (363 bp), WT1 (380 bp), PRAME (154 bp), Survivin 
(129 bp), RHAMM (381 bp), hTERT (270 bp), CML66 (214 bp) and β actin (454 bp). The thick black lines on 
the gels delineate grouping of gels cropped from different parts of the same gel, or from different gels. Full 
length gels in Supplementary Fig. 1. Cropping: Proteinase, WT1 (Supplementary Fig. 1B), PRAME, Survivin 
(Supplementary Fig. 1C), RHAMM (Supplementary Fig. 1C,E), hTERT (Supplementary Fig. 1D,F), CML66 
(Supplementary Fig. 1F) and β actin (Supplementary Fig. 1F). Expression of Proteinase and WT1 are also shown 
in Supplementary Fig. 1A, and CML-66 Supplementary Fig. 1D.
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Figure 2. Peptide binding based on (A) experimental T2 cell line HLA A*02:01 stabilization assay (B) 
SYFPEITHI positional scoring matrix61 and (C,D) artificial neural networks-based affinity predictions in the 
immune epitope database IEDB62,64. Dark and light grey filling represent eLAAs and pLAAs, respectively. (E) 
Correlation of peptide ranking based on HLA-A*02:01 stabilization assay with the T2 cell line, SYFPEITHI 
scoring61 and artificial neural networks-based affinity predictions in the immune epitope database IEDB62.
Figure 3. IFNγ ELISpot assay of PBMCs from 4 HLA-A*02:01 healthy donors (white bars) and 8 HLA-
A*02:01 positive CML patients (dark grey bars). The cells were tested against the eLAA HLA-I peptides P540-
hTERT, P300-PRAME, P187-WT1, P165-RHAMM and P169-PROTEINASE 3 previously identified by reverse 
immunology (Table 2) and the pLAA HLA-I peptides P207-PININ, P130-LARP1, P378-TRRAP, P308-ROS1, 
P114-PSME3, P326-URP2, P141-MBOA7, P57-UHRF1 identified from the MUTZ3 DCs and THP1MФ HLA-I 
peptidomes by LC-MS/MS (Table 1). PBMCs without peptides served as a negative control. Data represented as 
Spots Forming Units (SFU) per 5 × 104 CD8+ T cells. Symbols represent individual data points.
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(9.5) > URP2 (8.5) > UHRF1 (7.5) > MBOAT7 (7) > TRRAP (6.5) > ROS1 3.6 for eLAAs and pLAAs, respec-
tively. For AML the order was PRTN3 (7.2) > TRRAP (7) > hTERT (6) > RHAMM (6) > WT1 (5) > PRAME 
(4.4) > ROS1 (3.8) and PININ (11) > LARP1 (10) > UHRF1 (9.2) > URP2 (8) > MBOAT7 (7.5) > TRRAP 
(7) > ROS1 (3.8) for eLAAs and pLAAs, respectively. The expression of the pLAAs LARP1, UHRF1, URP2 and 
MBOAT7 in AML was higher compared to all the eLAAs (Fig. 5). All the LAAs were expressed at low levels in all 
major normal human tissues based on a 10% gene expression intensity cutoff. Only hTERT, LARP1, PININ and 
WT1 were expressed beyond the 10% cutoff. Beyond this cutoff, hTERT was expressed in heart and skeletal mus-
cle, LARP1 in brain, retina, smooth muscle, small intestine, adipocyte and placenta, PININ in all major tissues 
besides skin, and WT1 in uterus (Fig. 6).
Protein interaction partners of the LAAs. High numbers of protein interaction partners and the inter-
action of LAAs between and among them may indicate vital roles in leukemia. The known protein interaction 
partners of the LAAs (eLAAs and pLAAs) had been originally identified from experimental data obtained with 
a variety of biochemical, biophysical and genetic techniques. We applied STRING as detailed in materials and 
methods. WT1, RHAMM, ROS1 and MBOAT7 had only two known interaction partners, PRAME and UHRF1 
3, PRTN3 4, URP2 6, and TERT, PININ, TRRAP and LARP1 10. (Fig. 7A,B). None of the LAAs were found to 
interact with each other, both at primary (directly via the first shell) (Fig. 7A,B) and at secondary level (indirectly 
via the second shell) (data not shown).
Discussion
The eLAAs in Table 2 together with survivin and CML 66 have been described as ideal candidates for targeted 
immunotherapeutic strategy for leukemia especially AML as they are expressed in most leukemic blasts includ-
ing leukemic stem cells, important for the leukemic phenotype, immunogenic and have shown clinical effective 
potential at peptide and protein level51. The identification of these eLAAs was based on the overexpression of their 
mRNAs in leukemia and the corresponding HLA-I peptides (Table 2) were identified by reverse immunology 
using T cell epitope prediction algorithms. In our previous analysis of HLA-I peptidomes of antigen presenting 
cell lines MUTZ3-derived immature and mature dendritic cells and THP1-derived macrophages by LC-MS/
MS30 we didn’t identify any HLA-I peptides from these eLAAs. Despite the fact that the expression of the eLAAs, 
Figure 4. Immunogenicity of the LAAs for the most frequent HLA alleles. HLA-A*01:01, HLA-A*02:01, HLA-
A*11:01, HLA-A*24:02, HLA-C*06:02, HLA-C*07:01 and HLA-C*07:02 that together represent more than 
90% of the human population. The immunogenicity was determined with NetMHCpan 4.0 in IEDB64 using a 
binding affinity threshold of IC50 (500 nM). The immunogenicity scores are presented as 1/IC50 (500 nM) with 
values of 0 to 1 for low to high immunogenicity. Dotted and continuous line represent eLAAs and pLAAs, 
respectively.
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excluding RHAMM and hTERT, were detectable in MUTZ3 DCs and/or THP1MФ. This tallies with previous 
studies that have shown that mRNA gene expression does no translate directly into HLA epitope presentation, 
and reflects a distorted picture of the situation on the cell surface as detectable for T cells29. In fact, HLA-I pep-
tides have even been identified without detectable mRNA expression of their source proteins29.
The eLAAs and HLA-I epitopes have shown promising results in terms of induction of specific T cell 
responses, however, with limited clinical responses14,18,21,26–28. The restrictions may be the choice of LAAs mostly 
based on mRNA gene expression profiles, the indirect HLA-I epitope identification criteria, and the use of single 
or limited number of LAAs and HLA-I epitopes, which limits the spectrum of inducible tumor-specific T cell 
responses. The use of a direct approach to identify HLA-I epitopes from pLAAs and higher number of LAAs and 
HLA-I epitopes for targeted immunotherapy for leukemia could enhance clinical effectiveness.
In a prior study, we used immunoaffinity purification of HLA-1 of the antigen presenting lines 
MUTZ3-derived immature and mature dendritic cells and THP1-derived macrophages together with LC-MS/
MS of the peptides extracted from the HLA-I30. In the current study, we identified HLA I-presented epitopes 
from these HLA I peptidomes of antigens that had been described for other malignancies and hematological 
indications31–49. We analyzed and compared the LAAs and HLA-I peptides in Table 2 (epitopes from eLAAs) with 
those in Table 1 (epitopes from pLAA) based on their experimental and predicted HLA-binding affinities, immu-
nogenicity, expression of their source proteins in leukemic cells vs normal human hematopoietic cells and normal 
major human tissues, and their protein interaction partners. All these analyses and comparisons are important 
to assess the suitability of LAAs and HLA-I epitopes as immunotherapeutic targets in leukemia, which should 
contain epitopes with high affinity for HLA, be highly immunogenic for induction of tumor-specific CD8 T cells, 
and be highly interconnected with essential pathways so that they cannot be down-regulated without damage to 
vital processes.
Though all HLA-I peptides had high HLA-binding affinities based on the T2 cell HLA-A*02:01 stabiliza-
tion assay, peptides P141-MBOAT7, P378-TRRAP and P57-URP2 from the pLAAs (Table 1) had higher bind-
ing affinities than P300-PRAME, P540-hTERT, P165-RHAMM and P169-PRTN 3 from the eLAAs (Table 2). 
By SYFPEITHI epitope prediction, all the peptides had high score between 25 and 30. Using ANNs in IEDB, 
P378-TRRAP, P57-UHFR1 and P141-MBOAT7 from pLAAs ranked higher than the P540-hTERT from eLAAs 
(Fig. 2). There was no correlation in the ranking of the 12 peptides with respect to their HLA binding among 
the four methods, T2 HLA stabilization assay, SYFPEITHI, and NetMHCpan 4.0 and ANN 4.0 in IEDB (Fig. 2). 
Figure 5. Gene expression profiles of the established leukemia-associated antigens (eLAAs) and potential 
leukemia-associated antigens (pLAAs) in CML, AML and normal human hematopoietic cells determined 
using Bloodspot50 and the datasets GSE13159 and GSE42519 for human CML and AML, and normal human 
hematopoietic cells, respectively.
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Figure 6. Gene expression profiles of the LAAs established leukemia-associated antigens (eLAAs) and potential 
leukemia-associated antigens (pLAAs) in normal human tissue analyzed and visualized using BioGPS (http://
biogps.org/) and geneAtlas U133A gcrma datasets. The dotted line indicated low gene expression intensity 
cutoff of 10%.
Figure 7. Known protein interaction partners of the LAAs established leukemia-associated antigens (eLAAs) 
and potential leukemia-associated antigens (pLAAs) determined using STRING version 11.066 for Homo sapiens 
with a medium score of 0.400 and a cutoff of 10 interaction partners. (A) Protein interaction partners of the 
eLAAs. (B) Protein interaction partners of the pLAAs.
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The lack of correlation may have different reasons. Of the four methods, only the HLA stabilization assay is an 
experimental assay that, although not measuring affinity directly, yields values strongly correlated with binding 
affinity. The prediction algorithms are based on different types of data and have different designs. SYFPEITHI 
as a position-specific scoring matrix basically computes likelihood of binding of a peptide to a given HLA based 
on the statistics of the amino acids at the different sequence positions, which ignores the sequence contexts. The 
ANNs, as other machine learning approaches, can in principle capture information on the sequence contexts but 
are based on training data sets for binders and non-binders. The positive training sets usually differ between the 
different ANNs and reflect the composition and histories of the data: training data with exclusively experimental 
peptidome sequences may result in different predictions than training data with a high proportion of predicted 
epitopes. Negative training data are usually difficult to come by and often binders for a different HLA allele are 
used. Moreover, ANNs may work with different data formats such as peptide sequences or binding kinetics. 
Notwithstanding the lack of strict correlation, P141-MBOAT7 and P378-TRRAP was highest ranked among the 
four methods and P165-RHAMM and ROS1 were lowest.
In ELISpot assays for the frequencies of LAA epitope-specific T cells, the responses were higher in CML 
patients compared to the healthy controls, dominated by HLA-I peptides from the pLAAs, and P187-WT1 and 
hTERT from eLAAs (Fig. 3). Even though there was no correlation between the peptide binding affinities and T 
cell responses, maybe due to limitation of peptide binding affinity prediction approaches mentioned, in tendency 
HLA-I peptides from pLAAs were stronger binders with higher T cell responses than those from eLAAs. Since in 
vitro studies often do not translate into clinical effectiveness52,53, a comparison of the HLA-I peptides from eLAAs 
and pLAAs in a clinical study would be vital.
The sources of LAAs are equally important as the HLA-I peptides. In this regards, the predicted overall immu-
nogenicity of the LAAs for the seven most frequent alleles combined was high and comparable between the 
eLAAs and pLAAs (Fig. 4). All the LAAs appear suitable as therapeutic targets in leukemia patients from the 
general human population.
mRNAs of all the LAAs were expressed in CML and AML cells, but the pLAAs at higher levels (Fig. 5). 
Comparing the gene expression profiles between leukemia cells and normal human hematopoietic cells, only 
WT1 and PRAME expression was significantly higher in leukemia cells compared to normal human hemato-
poietic cells, in CML only PRAME (Fig. 5). In addition, TERT, WT1, LARP1 and PININ and were found to 
be highly expressed in some normal human tissues (Fig. 6). Similar observations were reported for previous 
studies for TERT and WT154–56. For leukemia-targeted immunotherapy, especially peptide-based vaccines and 
TCR-based CARs, differential gene expression may only play a secondary role in target selection. Gene expres-
sion levels of the antigens do not correlate with the presentation of the epitopes from these antigens on the cell 
surface as detectable for T cells29. For instance, though WT1 is expressed in normal tissues such as gonads, kidney 
and normal hematopoietic cells54,55, it has been used in clinical trials for targeted immunotherapy especially 
peptide-based vaccine for leukemia without any serious immunologic adverse events being observed14,21.
Cancers can switch off genes/lose antigens as an immune escape mechanism57–59. As predicted from protein 
network studies, they are more likely to switch off antigens with low number of protein interaction partners. The 
higher the number of protein interaction partners a LAA has, the more vital the LAA may be for cancer cell sur-
vival. Such LAA could be a more suitable immunotherapeutic target for leukemia. In this regard, PININ, TERT, 
TRRAP and LARP1 had the highest number of interaction partners, PRTN3 and URP2 intermediate numbers 
and WT1, RHAMM, ROS1 and MBOAT7, PRAME and UHRF1 the least (Fig. 7). Furthermore, no LAAs were 
found to interact with each other, both at primary level (directly) and at secondary level (indirectly).
In conclusion, the results of this study highlight new potential targets for T cell-mediated immunotherapy 
(therapeutic vaccine and TCR-based CARs) for leukemia, and the analysis and comparative data may allow for 
more informed selection of LAAs and HLA-I epitopes. However, comparative studies in a clinical setup are nec-
essary. Furthermore, though mass spectrometry (MS)-based immunopeptidomics approaches yield a large and 
relatively unbiased portrait of the population of processed and presented peptides, technological limitations 
such as low sensitivity may need to be addressed to allow for identification of more new potential targets for T 
cell-mediated immunotherapy.
Materials and Methods
Cell lines. The acute myeloid leukemia cell line MUTZ3 (DMSZ GmbH, Braunschweig, Germany) and acute 
monocytic cell line THP1 (ATCC TIB-202) were cultured and differentiated to MUTZ3-derived immature and 
mature dendritic cells (MUTZ3 iDC and MUTZ3 mDC), and THP1 macrophage (THP1MФ) respectively, as 
detailed in supplementary methods. The T cell leukemia cell line Molt-4 (DSMZ, Braunschweig, Germany) and 
the TAP-deficient lymphoblastic cell line T2 (from Peter Cresswell, Yale, New Haven, CT, USA) used in the HLA-
A*02:01 peptide binding affinity assays were cultured in DMEM or RPMI 1640 medium (Invitrogen, Karlsruhe, 
Germany) supplemented with 10% heat-inactivated fetal calf serum and 1% penicillin/streptomycin at 37 °C 
under 8% CO2. MUTZ3 iDC, MUTZ3 mDC, THP1MФ, K562 and Molt-4 cells were harvested by 10 min cen-
trifugation at 800 × g, shock-frozen with liquid nitrogen and stored at −140 °C. K562 and Molt-4 were used for 
total RNA isolation and MUTZ3 iDC, MUTZ3 mDC and THP1MФ for pHLA extraction or total RNA isolation.
PBMCs from healthy volunteers and CML patients. The clinical material was used with approval by 
Charité ethics committee (Approval No. EA1/222/14 and EA1/026/14) and written informed consent by the 
patients and volunteer donors. All methods and procedures were performed in accordance with the relevant 
guidelines and regulations including the handling of primary clinical materials, and anonymization and pro-
cessing of patient-related information and data. HLA typing was carried out by the HLA typing laboratory, 
Charité - Universitätsmedizin Berlin. Peripheral blood of 4 HLA-A*02:01-positive healthy volunteers and 8 
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HLA-A*02:01-positive chronic myeloid leukemia (CML) patients was used to isolate PBMCs by density centrifu-
gation using Ficoll Paque (Biochrom, Berlin, Germany) and cryopreserved in FCS (Biochrom, Berlin, Germany) 
with 10% DMSO (Pierce, Illinois, USA) at −140 °C. For in vitro priming, PBMCs were pulsed with 10 µg/ml of 
each peptide in ExVivo 15 serum-free medium (Biowhitaker, Belgium) at 37 °C and 8% CO2. 50 U/ml of recombi-
nant human IL-2 (Chiron, Munich, Germany) was added to the cultures on day 1 and day 3. On day 8 the primed 
PBMCs were harvested, washed with PBS (Gibco, Grand Island, NY, USA) and counted before analysis in INFγ 
ELISpot assays detailed in supplementary methods and by flow cytometry.
Gene expression in THP1MФ and MUTZ3 DCs using RT-PCR. Total RNA was extracted from 
THP1MФ, MUTZ3 DCs, K562 and Molt-4 using Nucleospin RNA II purification kit (Macherey-Nagel, Duren, 
Germany) as per manufacturer’s instructions. 500 ng of DNase-treated RNA was used to prepare cDNAs using 
superscript III Reverse Transcriptase (Invitrogen, CA, USA). RT-PCR was carried out with 1 µl of cDNA with 
PRTN3-, WT1-, PRAME-, Survivin-, RHAMM-, hTERT-, CML66-, β actin-sequence specific forward and 
reverse primers (Table 3). PCR conditions were initial denaturation at 96 °C for 4 min, followed by 34 cycles of 
40 sec at 95 °C, 1 min at 55 °C to 68 °C, 40 sec at 72 °C, and a final extension step of 10 min at 72 °C. PCR prod-
ucts were analyzed by 1% agarose gel electrophoresis. Positive controls for RHAMM and hTERT were K562 and 
Molt-4 respectively.
Peptides. Clinically tested HLA-A*02:01-restricted LAA peptides (Table 2) had been previously identified 
from overexpressed genes in leukemia patients compared to health individuals, by reverse immunology using 
computer based T cell epitope prediction programs such as BIMAS60, SYFPEITHI61, or artificial neural networks 
(ANNs) in the immune epitope database (IEDB)62. These peptides together with new HLA-A*02:01-restricted 
LAA peptides identified from MUTZ3 DCs and THP1MФ HLA class I peptidomes (Table 1) together with a HIV 
polymerase peptide were synthesized with a purity >95% by EMC microcollections GmbH (Tübingen, Germany). 
DMSO (Pierce, Rockford, Illinois, USA) was used to dissolve the lyophilized peptides before storage at −20 °C.
T2 cell line HLA-A*02:01 binding assay. To determine the HLA-A*02:01 binding of the peptides in 
Tables 1 and 2 the TAP-deficient HLA-A*02:01-positive T2 lymphoma cell line was used as previously described63 
with minimal modifications detailed in Supplementary Methods. The P564-HIVpol peptide LLFGXPVYV and 
T2 cells without peptide was used as positive and negative control respectively.
Flow cytometric analysis of CD8+ T cells frequencies. To determine the CD8+ T cells frequencies 
in the PBMC from a healthy donor and CML patients, pre and post peptide-primed PBMCs were stained with 
fluorochrome-labeled monoclonal antibodies against CD8 (BD Bioscience, Heidelberg, Germany). The frequen-
cies of cells expressing this marker was determined with a FACS Calibur flow cytometer (Becton Dickinson, 
Heidelberg, Germany). CellQuest (Becton Dickinson, Heidelberg, Germany), and FlowJow (FlowJo LLC, Oregon, 
USA) software were used to process and analyze the data, respectively.
LAAs immunogenicity. To determine the immunogenicity of the LAAs, the NetMHCpan 4.0 algorithm 
in IEDB64 was used. The immunogenicity was determined for HLA-A*01:01, HLA-A*02:01, HLA-A*11:01, 
HLA-A*24:02, HLA-C*06:02, HLA-C*07:01 and HLA-C*07:02, individually and all combined. These alleles 
together are expressed in 90% of the population65. IC50(500) nM binding affinity threshold was used as threshold 
for immunogenicity, and immunogenicity scores were presented as 1/IC50(500) nM.
LAA gene expression in CML, AML, normal hematopoietic cells and tissues, and protein inter-
action partners. To determine the gene expression profiles of the LAAs in CML, AML, normal human 
hematopoietic cells and other major human tissues, as well as protein interaction partners, the bloodspot data-
base50 (a database of gene expression profiles for healthy and malignant hematopoietic cells and tissues), BioGPS 
(http://biogps.org/) and the search tool for the retrieval of interacting proteins (STRING version 11.0) data-
base66 (a database of known and predicted protein-protein interactions) were used respectively. The gene expres-
sion profiles were determined using bloodspot based on curated microarray data. The data for human CML 
and AML were from GSE13159.The samples were derived from bone marrow. The AML were with t(15; 17), 
inv(16)/t(16;16), t(8; 21), t(11q23)/MLL and had complex aberrant karyotypes, and analysed with Affymetrix 
HG-U133 Plus 2.0 GeneChips67,68. The data for human normal hematopoietic cells were from GSE42519, and 
derived from 34 healthy donors hybridized to Affymetrix HG-U133 Plus 2.0 GeneChips69. The gene expression 
profiles of normal major human tissues was determined using BioGPS (http://biogps.org/). The data are from 
gene ATLAS U133A, gcrma, derived from 79 human samples hybridized to Affymetrix HG-U133A gene chips70. 
A low gene expression intensity cutoff of 10% was used. STRING version 11.0 was used to determine known 
eLAAs and pLAAs protein interaction partners, experimentally determined from various biochemical, biophys-
ical and genetic techniques. A medium interaction score of 0.400 was applied with a cutoff of 10 interaction 
partners at primary level against Homo sapiens.
Statistical analysis. Paired student’s t-test was used to compare LAA gene expression for human CML and 
AML cells and the highest expression in normal human hematopoietic cells. The differences were indicated as 
significant when *p < 0.05.
Data Availability
For original data and detailed protocols, please contact peter.walden@charite.de. The peptidome data are depos-
ited in the Immune Epitope Database (IEDB) at https://www.iedb.org/, Dataset identifier 1030722.
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